Release date: 2015-08-19
According to research firm GlobalData, the global growth hormone deficiency (GHD) market will grow to $1.88 billion in 2024. In 2014, its market share was $1.26 billion. From the 2014 to 2024 decade, the global GHD market grew at a moderate annual compound growth rate (CAGR) with a CAGR of 4.08%.
GlobalData pointed out in a recent report that the growth of the growth hormone deficiency drug market mainly occurs in seven countries, namely the United States, France, Germany, Italy, Western extraction, the United Kingdom, Japan, and the growth driver is mainly long-acting growth hormone. The introduction of bio-modified drugs, this improved biopharmaceutical is expected to be approved for marketing in 2017.
Lakshmi Dharmarajan, a senior analyst with cardiovascular and metabolic disorders from GlobalData, said that improved growth hormone drugs reduce the number of doses administered to patients, and that while maintaining efficacy, they will significantly improve compliance among patients, especially children. This results in a better therapeutic effect, which is very attractive to the patient.
According to GlobalData's interviews with key opinion leaders, patients need daily injections of growth hormone drugs. The patient's dependence on drugs is a long-standing problem in the therapeutic field of growth hormone deficiency, and the patient's needs are far from being met. The pharmaceutical company has worked hard to develop a simple treatment option that will reduce the number of doses from once a day to once a week. In fact, of the 12 kinds of growth hormone deficiency drugs, 9 are long-acting growth hormone bio-modification drugs.
Once long-acting hormonal drugs are available, it is expected that patients who refuse to receive daily growth hormone drugs will switch to long-acting drugs, which will increase the rate of treatment for growth hormone deficiency. The global market for daily injections of recombinant growth hormone drugs is expected to grow at a compound annual growth rate of -5.95%, from $1.26 billion in 2014 to $684 million in 2024. However, the global long-acting growth hormone drug market in 2024 It is expected to reach about $1.2 billion.
It can be seen from the opinion of key opinion leaders that adult patients absorb long-acting growth hormone drugs faster than children, and this is also the case with long-acting drugs in other therapeutic areas. Initially doctors will limit the use of this improved long-acting drug among cancer survivors. The market prospects for long-acting growth hormone therapy are very optimistic.
Source: New Kangjie
Molecular Biolab Equipment,Seqstudio Genetic Analyzer,Gene Sequencer Forensic Testing Equipment,Lab Clinical Instrument
Nanjing Superyears Gene Technology Co., Ltd. , https://www.superyearsglobal.com